News

18.01.2018: The new Tissuehome homepage is now online.

 

Karl KuchlerName & Address
Mathias Müller – Full Professor of Veterinary Molecular Genetics and Biotechnology
Current Position: Head of Institute of Animal Breeding and Genetics
University of Veterinary Medicine Vienna , Department of Biomedical Sciences
Veterinärplatz 1, 1210 Vienna, Austria
Phone:  +43-1-25077-5620
e-mail:  mathias.mueller@vetmeduni.ac.at                                             ORCID: 0000-0002-7879-3552
Web:www.vetmeduni.ac.at; www.jak-stat.at
CV (PDF)

Main Research Interests
Since over one decade we are coordinating the Viennese JAK-STAT Consortium which has established itself as one of the leading groups worldwide in the study of signal transmission by the Janus kinases (JAKs) and signal transducers and activators of transcription (STATs). In particular, the generation and analysis of advanced transgenic mouse models has enabled the Consortium to contribute substantially to our understanding of the functions of JAKs and STATs in human disease. The work is of highly interdisciplinary in nature, with contributions from genetics, molecular biology, bioinformatics and human medicine. The results from Vienna and elsewhere have led to the recognition of the JAK-STAT pathway as one of the twelve core pathways in the initiation and progression of cancer and as one of the key pathways in the defence against infections. Our major interest is the JAK-STAT signaling network at the interface of immunity, inflammation and cancer. Currently the consortium is compiling NGS data sets for the generation of an integrated map of STAT1-6 and TYK2 dependencies on the chromatin architecture of immune cells. The focus of our group is on tyrosine kinase 2 (TYK2) and STAT1, the founder members of the JAK and STAT family, respectively.

Scientific Education & Career History
2008 - 2017       Head of Department of Biomedical Sciences at Vetmeduni Vienna
since 2006        Chairman of the Supervisary Board of Biomodels Austria (former Austrian Center of Biomodels and Transgenetics)
2005 - 2007       Head of Department of Agrobiotechnology IFA Tulln at the University of Natural Resources and Applied Life Sciences (BOKU), Vienna
2002 - 2016       Head of Institute of Biotechnology in Animal Production at the IFA Tulln
since 1998        Chair (C4 professorship) 'Veterinary Biotechnology and Molecular Genetics' and Head of Institute of Animal Breeding and Genetics, Vetmeduni Vienna
1996                  offered chair (C4 full professorship) for Animal Breeding and Genetics at the Tierärztliche Hochschule Hannover, Germany and offered position Full Professor of Animal Genetics at The Royal Veterinary and Agricultural University KVL, Copenhagen, Denmark
1994                  offered position (tenure track) Governor's Lectureship at St Mary's Hospital Medical School (Imperial College of Science, Technology and Medicine in the University of London), London, UK
1994 - 1998       associate professor at the Institute of Animal Breeding and Genetics of the University of Veterinary Medicine Vienna, Austria and deputy head of the Department of Biotechnology in Animal Production at the IFA Tulln, Austria
1991 - 1993       postdoctoral fellowship at the Imperial Cancer Research Fund (now Cancer Research UK), London UK in the Biological Regulatory Mechanisms Laboratory, headed by Ian M. Kerr, PhD, FRS and George R. Stark
1990                  postdoctoral fellow at the Department of Molecular Animal Breeding (Prof. Gottfried Brem) and the Institute of Biochemistry (Prof. Ernst-Ludwig Winnacker) at the LMU Munich
1986 - 1989       PhD thesis at the Deptartment of Molecular Animal Breeding, LMU Munich and the Institute of Biochemistry, LMU Munich; Ph.D. defense with “first class honors” (summa cum laude).
1980-1988         Sudies of Veterinary Medicine at the Ludwig Maximilians University Munich

Experience in Scientific Management and Organization & Student Supervision
Since 1990        Supervision & training of > 20 PhD students
Since 2000        Member of the ‘Senat’ of Vetmeduni Vienna and member of various committees for organisation and (re-)structuring the pre- and postgraduate studies of Veterinary Medicine, BSc and MSc Comparative Biomedicine and Biotechnology at Vetmeduni Vienna
2006 - 2008       Scientific Member of the Governing Council of the Roslin Institute Edinburgh UK
2006 - 2016       Speaker and Coordinator of the Austrian Science Fund FWF Special Research Program SFB ‘Jak-Stat Signalling: From Basics to Disease’
2010                  Co-organizer, FEBS Special Meeting on Jak-Stat Signalling: from Basics to Disease, Vienna, Austria
2014                  Local organizing committee 28th Annual Conference of the European Macrophages and Dendritic Cell Society (EMDS), Vienna, Ausria
since 2015        Co-organizer, International Conference on Cytokine Signaling in Cancer, Aegean Conferences
2017 - 2012       Speaker and coordinator of the Austrian Science Fund FWF Special Research Program SFB ‘Monarchies and Hierarchies in Shaping Chromatin Landscapes’

Supervision of Doctoral (PhD) Thesis Students (past five years – 7 since 2005)
Eva Hainzl PhD Student 2009 – 2014
"Analysis of tyrosine kinase 2 in acute intestinal inflammation“
Mario Biaggio PhD Student 2011 – 2016
"The role of STAT1 and STAT3 in macrophages during cytomegalovirus infection“
Kerstin Schön PhD Student 2012 – 2016
"Analysis of microbial communities in dairy processing floor drains“
Natalija Simonovic  PhD Student 2014 – ongoing
"Fine tuning the reverse genetics of TYK2”
Ana Puga – PhD Student – 2014 - ongoing
"STAT1 isoform specificity in innate and adaptive immunity”
Stefen Shoebridge – PhD Student 2016 - ongoing
"TYK2 and immune cell cross talks in tumor surveillance“
Anzhelika Karjalainen – PhD Student 2016 - ongoing
"TYK2 and kinase-inactive TYK2 in NK cell tumor surveillance“
Katharina Wöss – PhD Student 2016 - ongoing
"Germline mutated TYK2 in hematopoietic tumorigenesis“

Invited Conference Lectures (5 recent selected)

  • 2017 - Invited Speaker at the 2nd International Conference on Cytokine Signaling in Cancer, Aegean Conferences, Heraklion, Greece
  • 2015 - Invited Speaker at the 1st International Conference on Cytokine Signaling in Cancer, Aegean Conferences, Chania, Greece
  • 2014 - Invited Speaker Joint Symposium between Taiwan-Austria Research Community, Taipeh, Taiwan
  • 2013 - Invited Speaker 2nd FEBS Special Meeting on JAK-STAT, Nottingham UK

Honors & Awards (5 most relevant)

1987 - 1990    'Stipendium nach dem Gesetz zur Förderung des wissenschaftlichen und künstlerischen Nachwuchses' (Stipend for promoting talented students in sciences and the arts), Munich, Bavaria
1991 - 1992    Fellow of the European Molecular Biology Organization (EMBO Long Term Fellowship)
1993                Fellow of the Commission of the European Communities (CEC Fellowship at Senior Level in the Framework of the Medical Research Programme)
2001                elected member of the german Nationale Akademie der Wissenschaften Leopoldina (www.leopoldina.org)

Member of Reviewing Panels, Editorial Boards, Scientific Organizations (5 selected)
2017 - 2019    Appointment to the Senat (Scientific Advisory Board) of the Christian Doppler Research Society (CDG), Austria
since 2013      Member of the Committee for the Stipend Programs of the Austrian Academy of Sciences ÖAW
2008 - 2015     Member of the Scientific Advisary Board of the Roslin Institute UK
2007 - 2014    Scientific consultant for the Institute of Science and Technology Austria (IST Austria)
2004 - 2016    Member of the scientific board of the Bavarian Ministry of Science, Research and Arts funding ‘BayGene’ (Bavarian Genome Research Networks)
2004 - 2008    Member of the scientific board of the Federal Ministry of Education and Research of Germany funding ‘FUGATO’ (Functional Genome Analysis of Animal Organisms)
2003 - 2011     Member of the curatorship of the Austrian Science Foundation (FWF)
since 2003      Reviewer for the German Research Funding Agency (Deutsche Forschungsgemeinschaft, DFG), the French National Research Agency (ANR), Slovak Academy of Sciences, Slowenian Research Agency, a.o.

Most Important Research Funding (selection of most relevant in past 5 years)

  • Austrian Science Funds: FWF-SFB F61, 2017-2021, Special research programme ‘Monarchies and Hierarchies in Shaping Chromatin Landscapes’; Co-ordination project and subproject (1.5 Mio € and 0.4 Mio €)
  • EC Seventh Framework Programme Infect-ERA ‚eDEVILLI’, 2015-18 (300 k€)
  • FWF SFB ‚JakStat Signaling’ (Coordinator and Project Leader), 2006-16 (3.9 Mio € and 1.0 Mio €)
  • FWF DK ‚Inflammation and Immunity’, 2010-19 (360 k€)
  • BM_WFa GEN-AU ‚Austromouse’, 2006-2012 (480 k€)
  • BM_WFa GEN-AU ‚InflammaBiota’, 2009-2012 (340 k€)

Key International Collaborators (selection of 5 with joint publications since 2012)

  • David E. Levy     New York University School of Medicine, NY USA - david.levy@nyumc.org
  • Ofer Mandelboim Hebrew University Hadassah Medical School, Jerusalem, Il - oferm@ekmd.huji.ac.il
  • Olli Silvennoinen   Institute of Biotechnology, University of Helsinki, FI - Olli.Silvennoinen@uta.fi

List of Publications (2012 - 2016)
Overall, > 200 original publications, several (co-)edited books and book chapters.

1. Crncec, I., Modak, M., Gordziel, C., Svinka, J., Scharf, I., Moritsch, S., Pathria, P., Schlederer, M., Kenner, L., Timelthaler, G., Muller, M., Strobl, B., Casanova, E., Bayer, E., Mohr, T., Stockl, J., Friedrich, K., and Eferl, R. (2018). Stat1 is a sex-specific tumor suppressor in colitis-associated colorectal cancer. Mol Oncol 12, 514-528. doi: 10.1002/1878-0261.12178.
2. Pham, H.T.T., Maurer, B., Prchal-Murphy, M., Grausenburger, R., Grundschober, E., Javaheri, T., Nivarthi, H., Boersma, A., Kolbe, T., Elabd, M., Halbritter, F., Pencik, J., Kazemi, Z., Grebien, F., Hengstschlager, M., Kenner, L., Kubicek, S., Farlik, M., Bock, C., Valent, P., Muller, M., Rulicke, T., Sexl, V., and Moriggl, R. (2018). STAT5BN642H is a driver mutation for T cell neoplasia. J Clin Invest 128, 387-401. doi: 10.1172/JCI94509.
3. Porpaczy, E., Tripolt, S., Hoelbl-Kovacic, A., Gisslinger, B., Bago-Horvath, Z., Casanova-Hevia, E., Clappier, E., Decker, T., Fajmann, S., Fux, D.A., Greiner, G., Gueltekin, S., Heller, G., Herkner, H., Hoermann, G., Kiladjian, J.J., Kolbe, T., Kornauth, C., Krauth, M.T., Kralovics, R., Muellauer, L., Mueller, M., Prchal-Murphy, M., Putz, E.M., Raffoux, E., Schiefer, A.I., Schmetterer, K., Schneckenleithner, C., Simonitsch-Klupp, I., Skrabs, C., Sperr, W.R., Staber, P.B., Strobl, B., Valent, P., Jaeger, U., Gisslinger, H., and Sexl, V. (2018). Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood doi: 10.1182/blood-2017-10-810739.
4. Wagner, M., Skandamis, P., Allerberger, F., Schoder, D., Lassnig, C., Muller, M., and Rychli, K. (2018). The impact of shelf life on exposure as revealed from quality control data associated with the quargel outbreak. Int J Food Microbiol 279, 64-69. doi: 10.1016/j.ijfoodmicro.2018.04.031.
5. Willmann, M., Hadzijusufovic, E., Hermine, O., Dacasto, M., Marcanto, L., Bauer, K., Peter, B., Gamperl, S., Eisenwort, G., Jensen-Jarolim, E., Müller, M., Arock, M., Vail, D.M., and Valent, P. (2018). Recent Advances in Comparative Oncology: the Paradigmatic Example of Canine and Human Mast Cell Neoplasms. Vet Comp Oncol. accepted
6. Wingelhofer, B., Neubauer, H.A., Valent, P., Han, X., Constantinescu, S., Gunning, P.T., Müller, M., and Moriggl, R. (2018). Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer. Leukemia. doi: 10.1038/s41375-018-0117-x. [review]
7. Leitner, N.R., Witalisz-Siepracka, A., Strobl, B., and Müller, M. (2017). Tyrosine kinase 2 - surveillant of tumours and bona fide oncogene. Cytokine 89, 209-218. pii: S1043-4666(15)30086-7. doi: 10.1016/j.cyto.2015.10.015. [review]
8. Linke, M., Pham, H., Katholnig, K., Schnöller, T., Miller, A., Demel, F., Schütz, B., Rosner, M., Kovacic, B., Sukhbaatar, N., Niederreiter, B., Blüml, S., Kuess, S., Sexl, V., Müller, M., Weckwerth, W., Haschemi, A., Susani, M., Hengstschläger, M., Gambello, M., and Weichhart, T. (2017). Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression. Nat Immunol 18, 293-302. doi: 10.1038/ni.3655
9. Majoros, A., Platanitis, E., Kernbauer-Holzl, E., Rosebrock, F., Muller, M., and Decker, T. Canonical and Non-Canonical Aspects of JAK-STAT Signaling: Lessons from Interferons for Cytokine Responses. Front Immunol 8, 29. doi: 10.3389/fimmu.2017.00029 [review]
10. Meissl, K., Macho-Maschler, S., Müller, M., and Strobl, B. (2017). The good, the bad and the unknown faces of STAT1 in carcinogenesis. Cytokine 89, 12-20. pii: S1043-4666(15)30099-5. doi: 10.1016/j.cyto.2015.11.011 [review]
11. Castiglia, V., Piersigilli, A., Ebner, F., Janos, M., Goldmann, O., Damböck, U., Kröger, A., Weiss, S., Knapp, S., Jamieson, A., Kirschnig, C., Kalinke, U., Strobl, B., Müller, M., Stoiber, D., Lienenklaus, S., and Kovarik, P. (2016). Type I Interferon Signaling Prevents Lethal Systemic IL-1 Signaling-Driven Hyperinflammation during Invasive Bacterial Infection of Soft Tissue. Cell Host Microbe 19, 375-387. doi: 10.1016/j.chom.2016.02.003.
12. Gotthardt, D., Putz, E.M., Grundschober, E., Prchal-Murphy, M., Straka, E., Kudweis, P., Heller, G., Bago-Horvath, Z., Witalisz-Siepracka, A., Cumaraswamy, A.A., Gunning, P.T., Strobl, B., Müller, M., Moriggl, R., Stockmann, C., and Sexl, V. (2016). STAT5 is a key regulator in NK cells and acts as molecular switch from tumor surveillance to tumor promotion. Cancer Discov 6, 414-429. doi: 10.1158/2159-8290.CD-15-0732
13. Maier, B.B., Hladik, A., Lakovits, K., Korosec, A., Martins, R., Kral, J.B., Mesteri, I., Strobl, B., Muller, M., Kalinke, U., Merad, M., and Knapp, S. (2016). Type I interferon promotes alveolar epithelial type II cell survival during pulmonary S. pneumoniae infection and sterile lung injury in mice. Eur J Immunol 46, 2175-2186. doi: 10.1002/eji.201546201
14. Majoros, A., Platanitis, E., Szappanos, D., Cheoan, H.J., Vogl, C., Shukla, P., Stark, G.R., Sexl, V., Schreiber, R.D., Schindler, C., Müller, M., and Decker, T. (2016). Response to interferons and antibacterial innate immunity in absence of tyrosine-phosphorylated STAT1. EMBO Rep 17, 367-382. doi: 10.15252/embr.201540726.
15. Putz, E.M., Majoros, A., Gotthart, D., Zebedin-Brandl, E., Prchal-Murphy, M., Eisinger, D.A., Schlattl, A., Schreiber, R.D., Carotta, S., Müller, M., Gerner, C., Decker, T., and Sexl, V. (2016). Novel non-­canonical role of STAT1 in Natural Killer cell cytotoxicity. OncoImmunology 5: e1186314. doi: 10.1080/2162402X.2016.1186314
16. Schön, K., Schornsteiner, E., Dzieciol, M., Wagner, M., Müller, M., and Schmitz-Esser, S. (2016). Microbial communities in dairy processing environment floor drains are dominated by product-associated bacteria and yeasts. Food Cont 70, 210-215. doi: 10.1016/j.foodcont.2016.05.057
17. Zotz, J.S., Wölbing, F., Lassnig, C., Kauffmann, M., Schulte, U., Kolb, A., Whitelaw, B., Müller, M., Biedermann, T., and Huber, M. (2016). CD13/aminopeptidase N is a negative regulator of mast cell activation. FASEB J 30, 2225-2235. doi: 10.1096/fj.201600278
18. Bakiri, L., Macho-Maschler, S., Custic, I., Niemiec, J., Guio-Carrion, A., Hasenfuss, S.C., Müller, M., Beug, H., and Wagner, E. (2015). Fra-1/AP-1 induces mammary epithelial cell EMT by modulating Zeb1/2 and TGFbeta expression. Cell Death Diff 22, 336-350. DOI: 10.1038/cdd.2014.157
19. Berry, D., Kuzyk, O., Rauch, I., Heider, S., Schwab, C., Hainzl, E., Decker, T., Müller, M., Strobl, B., Schleper, C., Urich, T., Wagner, M., Kenner, L., and Loy, A. (2015). Intestinal microbiota signatures associated with inflammation history in mice experiencing recurring colitis. Front Microbiol 6, 1408. doi: 10.3389/fmicb.2015.01408
20. Gilbert, S., Nivarthi, H., Mayhew, C.N., Lo, Y.H., Noah, T.K., Vallance, J., Rulicke, T., Muller, M., Jegga, A.G., Tang, W., Zhang, D., Helmrath, M., Shroyer, N., Moriggl, R., and Han, X. (2015). Activated STAT5 Confers Resistance to Intestinal Injury by Increasing Intestinal Stem Cell Proliferation and Regeneration. Stem Cell Rep 4, 209-225. doi: 10.1016/j.stemcr.2014.12.004
21. Hainzl, E., Stockinger, S., Rauch, I., Heider, S., Berry, D., Lassnig, C., Schwab, C., Rosebrock, F., Milinovich, G., Schlederer, M., Wagner, M., Schleper, C., Loy, A., Urich, T., Kenner, L., Han, X., Decker, T., Strobl, B., and Müller, M. (2015). Intestinal epithelial cell tyrosine kinase 2 transduces interleukin-22 signals to protect from acute colitis. J Immunol 195, 5011-5024. DOI: 10.4049/jimmunol.1402565
22. Leopold Wager, C.M., Hole, C.R., Wozniak, K.L., Olszewski, M.A., Müller, M., and Wormley Jr., F.L. (2015). STAT1 Signaling within Macrophages is Required for Anti-fungal Activity against Cryptococcus neoformans. Infect Immun 83, 4513-4527. doi:10.1128/IAI.00935-15
23. Pathria, P., Gotthardt, D., Prchal-Murphy, M., Putz, E.M., Holcmann, M., Schlederer, M., Grabner, B., Crncec, I., Svinka, J., Musteanu, M., Hoffmann, T., Filipits, M., Berger, W., Poli, V., Kenner, L., Bilban, M., Casanova, E., Müller, M., Strobl, B., Bayer, E., Mohr, T., Sexl, V., and Eferl, R. (2015). Myeloid STAT3 promotes formation of colitis-associated colorectal cancer in mice. Oncoimmunology 4, e998529. DOI: 10.1080/2162402X.2014.998529
24. Prchal-Murphy, M., Witalisz-Siepracka, A., Bednarik, K.T., Putz, E.M., Gotthardt, D., Meissl, K., Sexl, V., Müller, M., and Strobl, B. (2015). In vivo tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity. Oncoimmunology 4, e1047579. DOI: 10.1080/2162402X.2015.1047579
25. Rauch, I., Rosebrock, F., Hainzl, E., Heider, S., Majoros, A., Wienerroither, S., Strobl, B., Stockinger, S., Staeheli, P., Kenner, L., Müller, M., and Decker, T. (2015). Non canonical effects of IRF9 in intestinal inflammation: more than type I and type III interferons. Mol Cell Biol 35, 2332-2343. DOI: 10.1128/MCB.01498-14
26. Shukla, P., Vogl, C., Wallner, B., Rigler, D., Müller, M., and Macho-Maschler, S. (2015). High-Throughput mRNA and miRNA Profiling of Epithelial-Mesenchymal Transition in MDCK cells. BMC Genomics 16, 944. DOI: 10.1186/s12864-015-2036-9
27. Smetko, A., Soudre, A., Silbermayr, K., Muller, S., Brem, G., Hanotte, O., Boettcher, P.J., Stella, A., Meszaros, G., Wurzinger, M., Curik, I., Muller, M., Burgstaller, J., and Solkner, J. (2015). Trypanosomosis: potential driver of selection in African cattle. Front Genet 6, 137. DOI: 10.3389/fgene.2015.00137
28. Stiedl, P., Mc Mahon, R., Blaas, L., Stanek, V., Svinka, J., Grabner, B., Zollner, G., Claudel, T., Müller, M., Mikulits, W., Esterbauer, H., Eferl, R., Haybaeck, J., Trauner, M., and Casanova, E. (2015). Growth hormone resistance exacerbates cholestasis-induced murine liver fibrosis. Hepatology 61, 613-626. DOI: 10.1002/hep.27408
29. Üstün, S., Lassnig, C., Preitschopf, A., Mikula, M., Müller, M., Hengstschläger, M., and Weichhart, T. (2015). Effects of the mTOR inhibitor everolimus and the PI3K/mTOR inhibitor NVP-BEZ235 in murine acute lung injury models. Transpl Immunol 33, 45-50. DOI: 10.1016/j.trim.2015.06.001
30. Wienerroither, S., Shukla, P., Farlik, M., Majoros, A., Stych, B., Vogl, C., Cheon, H., Stark, G.R., Strobl, B., Müller, M., and Decker, T. (2015). Cooperative transcriptional activation of antimicrobial genes by STAT and NFκB pathways through concerted recruitment of the mediator complex. Cell Rep 12, 300-312. DOI: 0.1016/j.celrep.2015.06.021
31. Bosmann, M., Russkamp, N.F., Strobl, B., Roewe, J., Balouzian, L., Pache, F., Radsak, M.P., van Rooijen, N., Zetoune, F.S., Sarma, J.V., Núnez, G., Müller, M., Murray, P.J., and Ward, P.A. (2014). Interruption of macrophage-derived IL-27(p28) production by IL-10 during sepsis requires STAT3 but not SOCS3. J Immunol 193, 5668-5677. DOI: 10.4049/jimmunol.1302280
32. Bosmann, M., Strobl, B., Kichler, N., Pache, F., Murray, P.J., Müller, M., and Ward, P.A. (2014). Tyrosine kinase 2 promotes sepsis-associated lethality by facilitating production of interleukin-27. J Leukoc Biol 96, 123-131. DOI: 10.1189/jlb.3A1013-541R
33. Gotthardt, D., Putz, E.M., Straka, E., Kudweis, P., Baggio, M., Poli, V., Strobl, B., Müller, M., and Sexl, V. (2014). Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance. Blood 124, 2370-2379. DOI: 10.1182/blood-2014-03-564450
34. Grunert, T., Monahan, A., Lassnig, C., Vogl, C., Strobl, B., Müller, M., and Ehling-Schulz, M. (2014). Deciphering host genotype-specific impacts on the metabolic fingerprint of Listeria monocytogenes by FTIR spectroscopy. PLoS One 9, e115959. DOI: 10.1371/journal.pone.0115959
35. Keil, E., Finkenstädt, D., Wufka, C., Trilling, M., Liebfried, P., Strobl, B., Müller, M., and Pfeffer, K. (2014). Important scaffold function of the Janus kinase 2 uncovered by a novel mouse model harboring a Jak2 activation loop mutation. Blood 123, 520-529. DOI: 10.1182/blood-2013-03-492157
36. Kovacic, B., Hoelbl-Kovacic, A., Fischhuber, K.M., Leitner, N.R., Gotthardt, D., Casanova, E., Sexl, V., and Müller, M. (2014).
A fate-tracing mouse model to distinguish between myeloid and lymphoid lineages. Haematologica 99, 1006-1015. DOI: 10.3324/haematol.2013.097154
37. Leitner, N.R., Lassnig, C., Rom, R., Heider, S., Bago-Horvath, Z., Eferl, R., Müller, S., Kolbe, T., Kenner, L., Rülicke, T., Strobl, B., and Müller, M. (2014). Inducible, dose-adjustable and time-restricted reconstitution of Stat1 deficiency in vivo. PLoS One 29, e86608. DOI: 10.1371/journal.pone.0086608
38. Liehl, P., Zuzarte-Luís, V., Chan, J., Zillinger, T., Baptista, F., Carapau, D., Konert, M., Hanson, K.K., Carret, C., Lassnig, C., Müller, M., Kalinke, U., Saeed, M., Ferreira Chora, A., Golenbock, D.T., Strobl, B., Prudencio, M., Coelho, L.P., Kappe, S.H., Superti-Furga, J., Pichlmair, A., Vigário, A.M., Rice, C.M., Fitzgerald, K.A., Barchert, W., and Mota, M.M. (2014). Host-cell sensors for Plasmodium activate innate immunity against liver-stage infection. Nat Med 20, 47-53. DOI: 10.1038/nm.3424
39. Rauch, I., Hainzl, E., Rosebrock, F., Heider, S., Schwab, C., Berry, D., Stoiber, D., Wagner, M., Schleper, C., Loy, A., Urich, T., Muller, M., Strobl, B., Kenner, L., and Decker, T. (2014). Type I interferons have opposing effects during the emergence and recovery phases of colitis. Eur J Immunol 44, 2749-2760. DOI: 10.1002/eji.201344401
40. Schwab, C., Berry, D., Rauch, I., Rennisch, I., Ramesmayer, J., Hainzl, E., Heider, S., Decker, T., Kenner, L., Müller, M., Strobl, B., Wagner, M., Schleper, C., Loy, A., and Urich, T. (2014). Longitudinal study of murine microbiota activity and interactions with the host during acute inflammation and recovery. ISME J 8, 1101-1114. DOI: 10.1038/ismej.2013.223
41. Semper, C., Leitner, N.R., Lassnig, C., Parrini, M., Mahlakoiv, T., Rammerstorfer, M., Lorenz, K., Rigler, D., Müller, S., Kolbe, T., Vogl, C., Rülicke, T., Staeheli, P., Decker, T., Müller, M., and Strobl, B. (2014). STAT1β is not dominant negative and is capable of contributing to IFNγ-dependent innate immunity. Mol Cell Biol 34, 2235-2248. DOI: 10.1128/MCB.00295-14
42. Übel, C., Graser, A., Koch, S., Rieker, R.J., Lehr, H.A., Müller, M., and Finotto, S. (2014). Role of Tyk-2 in Th9 and Th17 cells in allergic asthma. Sci Rep 4, 5865. DOI: 10.1038/srep05865
43. Vielnascher, R.M., Hainzl, E., Leitner, N.R., Rammerstorfer, M., Popp, D., Witalisz, A., Rom, R., Karaghiosoff, M., Kolbe, T., Müller, S., Rülicke, T., Lassnig, C., Strobl, B., and Müller, M. (2014). Conditional ablation of TYK2 in immunity to viral infection and tumor surveillance. Transgenic Res 23, 519-529. DOI: 10.1007/s11248-014-9795-y
44. Wienerroither, S., Rauch, I., Rosebrock, F., Jamieson, A.M., Bradner, J., Muhar, M., Zuber, J., Müller, M., and Decker, T. (2014). Regulation of NO synthesis, local inflammation and innate immunity to pathogens by BET family proteins. Mol Cell Biol 34, 415-427. DOI: 10.1128/MCB.01353-13

 

10 Most Important Career Publications (only as first or corresponding author)

  1. Hainzl, E., Stockinger, S., Rauch, I., Heider, S., Berry, D., Lassnig, C., Schwab, C., Rosebrock, F., Milinovich, G., Schlederer, M., Wagner, M., Schleper, C., Loy, A., Urich, T., Kenner, L., Han, X., Decker, T., Strobl, B., and Müller, M. (2015). Intestinal epithelial cell tyrosine kinase 2 transduces interleukin-22 signals to protect from acute colitis. J Immunol 195, 5011-5024. DOI: 10.4049/jimmunol.1402565
  2. Prchal-Murphy, M., Semper, C., Lassnig, C., Wallner, B., Gausterer, C., Teppner-Klymiuk, I., Kobolak, J., Müller, S., Kolbe, T., Karaghiosoff, M., Dinnyes, A., Rülicke, T., Leitner, N.R., Strobl, B., and Müller, M. (2012). TYK2 Kinase Activity Is Required for Functional Type I Interferon Responses In Vivo. PLoS One 7, e39141. DOI: 10.1371/journal.pone.0039141
  3. Vogl, C., Flatt, T., Fuhrmann, B., Hofmann, E., Wallner, B., Stiefvater, R., Kovarik, P., Strobl, B., and Müller, M. (2010). Transcriptome analysis reveals a major impact of JAK protein tyrosine kinase 2 (Tyk2) on the expression of interferon-responsive and metabolic genes. BMC Genomics 11, 199. DOI: 10.1186/1471-2164-11-199
  4. Costantino, G., Egerbacher, M., Kolbe, T., Karaghiosoff, M., Strobl, B., Vogl, C., Helmreich, M., and Müller M. (2008) Tyk2 and Stat1 contribute to intestinal ischemia/reperfusion (I/R) injury. Shock 29, 238-244.
  5. Lassnig, C., Sanchez, C.M., Egerbacher, M., Walter, I., Majer, S., Kolbe, T., Pallares, P., Enjuanes, L., Müller, M. (2005) Development of a transgenic mouse model susceptible to human coronavirus 229E. Proc Natl Acad Sci USA 102, 8275-8280.
  6. Strobl, B., Bubic, I., Bruns, U., Steinborn, R., Lajko, R., Kolbe, T., Karaghiosoff, M., Kalinke, U., Jonjic, S., Müller, M. (2005). Novel functions of Tyk2 in the antiviral defense against murine cytomegalovirus. J Immunol 175, 4000-4008.
  7. Karaghiosoff, M., Steinborn, R., Kovarik, P., Kriegshäuser, G., Baccarini, M., Donabauer, B., Reichart, U., Kolbe, T., Bogdan, C., Leanderson, T., Levy, D., Decker, T., and Müller, M. (2003). Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock. Nat Immunol 4, 471-477.
  8. Karaghiosoff, M., Neubauer, H., Lassnig, C., Kovarik, P., Schindler, H., Pircher, H., McCoy, B., Bogdan, C., Decker, T., Brem, G., Pfeffer, K., and Müller, M. (2000). Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 13, 549-560.
  9. Müller, M., Briscoe, J., Laxton, C., Guschin, D., Ziemicki, A., Silvennoinen, O., Harpur, A.G., Barbieri, G., Witthuhn, B.A., Schindler, C., Pellegrini, S., Wilks, A.F., Ihle, J.N., Stark, G.R. and Kerr, I.M. (1993). The protein tyrosine kinase JAK1 complements defects in the interferon- and signal transduction. Nature 366, 129-135.
  10. Müller, M., Laxton, C., Briscoe, J., Schindler, C., Improta, T., Darnell, J.E., Jr., Stark, G.R. and Kerr, I.M. (1993). Complementation of a mutant cell line: central role of the 91-kDa polypeptide of ISGF3 in the interferon- and - signal transduction pathways. EMBO J 12, 4221-4228.